Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single-Arm, Multi-Center, Phase II Study of Troxatyl™ (Troxacitabine) Administered by Continuous Infusion in Patients With Acute Myeloid Leukemia (AML) in Second Salvage

NCT00129948 is registered in ClinicalTrials.gov with SGX Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00129948
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00129948 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single-Arm, Multi-Center, Phase II Study of Troxatyl™ (Troxacitabine) Administered by Continuous Infusion in Patients With Acute Myeloid Leukemia (AML) in Second Salvage
Lead sponsor
SGX Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2005
Completion date
October 31, 2007
Enrollment
211
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, myeloid, acute